JPMorgan Chase & Co. Purchases 73,389 Shares of LifeMD, Inc. (NASDAQ:LFMD)

JPMorgan Chase & Co. grew its stake in LifeMD, Inc. (NASDAQ:LFMD - Free Report) by 496.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,173 shares of the company's stock after buying an additional 73,389 shares during the period. JPMorgan Chase & Co. owned approximately 0.20% of LifeMD worth $462,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in LFMD. Barclays PLC grew its position in LifeMD by 311.7% in the third quarter. Barclays PLC now owns 49,017 shares of the company's stock worth $257,000 after acquiring an additional 37,112 shares in the last quarter. Geode Capital Management LLC lifted its stake in LifeMD by 11.4% during the third quarter. Geode Capital Management LLC now owns 819,233 shares of the company's stock worth $4,293,000 after purchasing an additional 83,598 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of LifeMD by 306.8% in the 3rd quarter. XTX Topco Ltd now owns 55,738 shares of the company's stock worth $292,000 after purchasing an additional 42,037 shares in the last quarter. State Street Corp increased its position in shares of LifeMD by 20.0% during the 3rd quarter. State Street Corp now owns 1,155,495 shares of the company's stock valued at $6,055,000 after purchasing an additional 192,861 shares during the last quarter. Finally, Centiva Capital LP purchased a new position in shares of LifeMD during the 3rd quarter valued at about $196,000. Institutional investors own 35.52% of the company's stock.

Analyst Ratings Changes

LFMD has been the topic of a number of recent research reports. HC Wainwright reiterated a "buy" rating and set a $12.00 price target on shares of LifeMD in a research report on Monday, November 11th. Lake Street Capital initiated coverage on shares of LifeMD in a report on Tuesday, December 10th. They set a "buy" rating and a $12.00 target price on the stock. KeyCorp lowered their price target on shares of LifeMD from $10.00 to $7.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Finally, Mizuho initiated coverage on LifeMD in a research note on Wednesday, December 4th. They set a "neutral" rating and a $7.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $11.14.

LifeMD Trading Down 3.0 %

Shares of LFMD stock traded down $0.17 during mid-day trading on Friday, reaching $5.57. The stock had a trading volume of 752,471 shares, compared to its average volume of 474,575. The stock's 50-day moving average price is $5.44 and its two-hundred day moving average price is $5.38. The firm has a market capitalization of $241.24 million, a PE ratio of -8.70 and a beta of 1.49. LifeMD, Inc. has a 52-week low of $3.99 and a 52-week high of $12.88.

LifeMD (NASDAQ:LFMD - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.05). The business had revenue of $53.39 million during the quarter, compared to analyst estimates of $53.53 million. During the same period last year, the firm earned ($0.20) earnings per share. On average, equities research analysts forecast that LifeMD, Inc. will post -0.56 earnings per share for the current year.

Insider Activity at LifeMD

In other LifeMD news, CEO Justin Schreiber sold 25,000 shares of the business's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $5.19, for a total transaction of $129,750.00. Following the transaction, the chief executive officer now directly owns 2,703,715 shares of the company's stock, valued at approximately $14,032,280.85. The trade was a 0.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 15.97% of the stock is owned by corporate insiders.

LifeMD Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.